Edition:
United States

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

13.15EUR
10:23am EDT
Change (% chg)

€0.07 (+0.54%)
Prev Close
€13.08
Open
€13.44
Day's High
€13.55
Day's Low
€13.15
Volume
82,203
Avg. Vol
169,250
52-wk High
€19.42
52-wk Low
€8.92

Chart for

About

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modi... (more)

Overall

Beta: 1.26
Market Cap(Mil.): €335.65
Shares Outstanding(Mil.): 24.55
Dividend: --
Yield (%): --

Financials

  MDG1k.DE Industry Sector
P/E (TTM): -- 99.04 30.20
EPS (TTM): -0.59 -- --
ROI: -11.22 3.31 12.77
ROE: -13.37 2.31 14.92

BRIEF -Medigene Raises 2018 Guidance After H1 Results

* NOW EXPECTS TO GENERATE TOTAL 2018 REVENUE OF BETWEEN EUR 9.5 - 10.5 MILLION

Aug 07 2018

German stocks - Factors to watch on May 15

BERLIN/FRANKFURT, May 15 The following are some of the factors that may move German stocks on Tuesday:

May 15 2018

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

FRANKFURT German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

May 14 2018

UPDATE 1-Medigene in for up to $1.5 bln under broader pact with Bluebird Bio

* Shares up 8 pct (Adds shares, background on technology, analyst comment)

May 14 2018

Medigene broadens alliance on T-cell receptors with Bluebird Bio

FRANKFURT, May 14 German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

May 14 2018

BRIEF-Medigene AG Medigene Appoints Dr. Kai Pinkernell To Executive Management Board As Cmo/Cdo

* MEDIGENE AG: MEDIGENE APPOINTS DR. KAI PINKERNELL TO EXECUTIVE MANAGEMENT BOARD AS CMO/CDO Source text for Eikon: Further company coverage:

Apr 11 2018

BRIEF-Medigene AG Says ‍Planned 2018 EBITDA Loss Of EUR 21 - 23 Mln​

* PTA-NEWS: MEDIGENE AG: MEDIGENE PUBLISHES 2017 ANNUAL REPORT AND ANNOUNCES START OF CLINICAL TRIAL WITH TCR IMMUNOTHERAPY MDG1011

Mar 22 2018

BRIEF-Medigene Receives Approvals For First Clinical Trial With MDG1011

* SAYS RECEIVES APPROVALS FOR ITS FIRST CLINICAL TRIAL WITH TCR THERAPY MDG1011

Feb 21 2018

Earnings vs. Estimates